Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $6.2B | $1.3B | $187M | $384M | 24.9% | -2.9% | -78.4% |
| 2024 | $6.4B | $1.6B | $864M | $588M | 183.1% | 2.2% | -15.5% |
| 2023 | $6.3B | $1.4B | $1.0B | $538M | -1461.4% | 1.4% | 11.6% |
| 2022 | $6.2B | $1.8B | $917M | $431M | -102.8% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 6,174 | 6,263 | 6,403 | 6,216 |
| Operating Revenue | - | 6,174 | 6,263 | 6,403 | 6,216 |
| Cost Of Revenue | - | 2,294 | 2,515 | 2,688 | 2,903 |
| Gross Profit | - | 3,880 | 3,748 | 3,715 | 3,313 |
| Operating Expense | - | 2,175 | 2,421 | 2,229 | 2,087 |
| Research And Development | - | 471 | 528 | 469 | 366 |
| Selling General And Administration | - | 1,704 | 1,893 | 1,760 | 1,721 |
| Total Expenses | - | 4,469 | 4,936 | 4,917 | 4,990 |
| Operating Income | - | 1,705 | 1,327 | 1,486 | 1,226 |
| EBITDA | - | 1,756 | 1,436 | 1,604 | 1,290 |
| Normalized EBITDA | - | 1,902 | 1,548 | 1,742 | 1,706 |
| EBIT | - | 1,544 | 1,200 | 1,327 | 929 |
| Interest Expense | - | 422 | 527 | 520 | 504 |
| Net Interest Income | - | -422 | -527 | -520 | -504 |
| Other Non Operating Income Expenses | - | -15 | -15 | -21 | 119 |
| Other Income Expense | - | -161 | -127 | -159 | -297 |
| Interest Expense Non Operating | - | 422 | 527 | 520 | 504 |
| Net Non Operating Interest Income Expense | - | -422 | -527 | -520 | -504 |
| Pretax Income | - | 1,122 | 673 | 807 | 425 |
| Tax Provision | - | 205 | -350 | -57 | 238 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -26.72 | -23.52 | -28.98 | -87.36 |
| Net Income Continuous Operations | - | 917 | 1,023 | 864 | 187 |
| Net Income From Continuing And Discontinued Operation | - | 917 | 1,023 | 864 | 187 |
| Net Income From Continuing Operation Net Minority Interest | - | 917 | 1,023 | 864 | 187 |
| Net Income | - | 917 | 1,023 | 864 | 187 |
| Net Income Common Stockholders | - | 917 | 1,023 | 864 | 187 |
| Net Income Including Noncontrolling Interests | - | 917 | 1,023 | 864 | 187 |
| Normalized Income | - | 1,036.28 | 1,111.48 | 973.02 | 515.64 |
| Diluted NI Availto Com Stockholders | - | 917 | 1,023 | 864 | 187 |
| Basic Average Shares | - | 254.08 | 255.24 | 257.05 | 259.50 |
| Diluted Average Shares | - | 255.17 | 256.27 | 259.15 | 260.76 |
| Reconciled Depreciation | - | 212 | 236 | 277 | 361 |
| Reconciled Cost Of Revenue | - | 2,294 | 2,515 | 2,688 | 2,903 |
| Total Unusual Items | - | -146 | -112 | -138 | -416 |
| Total Unusual Items Excluding Goodwill | - | -146 | -112 | -138 | -416 |
| Net Income Discontinuous Operations | 0 | 0 | 0 | - | - |
| Special Income Charges | - | -135 | -70 | -112 | -402 |
| Other Special Charges | - | 107 | 8 | 81 | 6 |
| Impairment Of Capital Assets | - | - | 0 | 0 | 301 |
| Restructuring And Mergern Acquisition | - | 28 | 62 | 31 | 95 |
| Gain On Sale Of Security | - | -11 | -42 | -26 | -14 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Organon & Co.this co. | OGN | $3.5B | 18.82β discount | 4.68 | 24.9% | 8.98 |
| Waystar Holding Corp. | WAY | $3.9B | 34.60 | 1.00 | 2.9% | 13.55 |
| Catalyst Pharmaceuticals, Inc. | CPRX | $3.8B | 17.87 | 4.01 | 22.5% | 10.56 |
| Merit Medical Systems, Inc. | MMSI | $3.8B | 29.27 | 2.37 | 8.1% | 12.46 |
| ACADIA Pharmaceuticals Inc. | ACAD | $3.7B |
| - |
| - |
| - |
| - |
| 9.51 |
| 3.03 |
| 31.9% |
| 30.83 |
| ICU Medical, Inc. | ICUI | $3.4B | 4607.08 | 1.59 | 0.0% | 14.73 |
| Concentra Group Holdings Parent, Inc. | CON | $3.2B | 19.16 | 8.11 | 42.3% | 12.74 |
| Integer Holdings Corporation | ITGR | $3.1B | 30.63 | 1.80 | 5.9% | 15.20 |
| Arcus Biosciences, Inc. | RCUS | $3.1B | -8.80 | 4.92 | -55.9% | -8.94 |
| Peer Median | - | 24.21 | 2.70 | 7.0% | 13.15 | |